

**“Design, Development and Characterization of Drug
Delivery System for Bioactive(s)”**

Executive summary of thesis submitted for the degree of

**DOCTOR OF PHILOSOPHY
IN
PHARMACY**

By

Samarth kumar (Reg. No.: FOPH/29)
M. Pharm (Industrial Pharmacy)

Under the Guidance of
Dr. Krutika K. Sawant
Professor and Ex. Head & Ex. Dean, Faculty of Pharmacy

Under the Co-guidance of
Dr. Ajay Khopade
Vice President & Head – Formulation R&D,
Sun Pharmaceutical Industries Limited

Submitted to



Faculty of Pharmacy,
The Maharaja Sayajirao University of Baroda,
Vadodara-390002, Gujarat, India.

March – 2025

CONTENTS OF THE THESIS

CONTENTS

Table of Content.....	I
List of Figures.....	VIII
List of Tables.....	XVII
Abbreviations.....	XXII
Abstract.....	XXX

TABLE OF CONTENT OF THE THESIS

CHAPTER-1

1.1	Peptide Therapeutics.....	1
1.1.1	Peptide therapeutics for addressing unmet needs in healthcare.....	2
1.2	Oxytocin.....	6
1.3	Vasopressin.....	7
1.4	Renin Angiotensin System (RAS).....	8
1.5	Ready to Infuse (RTI) Drug Delivery Systems.....	8
1.6	Nanocarriers-Based Delivery Approach.....	9
1.6.1	Nanocarriers mediated delivery of peptides to brain.....	10
1.7	Conjugation of Peptide Molecules to Enhance the Pharmacokinetics and Pharmacodynamic Attributes.....	12
1.8	Aims & Objectives.....	13
1.8.1	Aims.....	13
1.8.2	Ready to infuse (RTI) formulation.....	13
1.8.3	Nano-formulations for nose to brain delivery.....	13
1.8.4	Chemical modification to improve half-life and bioavailability of oxytocin	14
1.9	Objectives.....	14
1.9.1	Ready to infuse (RTI) drug delivery system.....	14
1.9.2	Nano-formulations for nose to brain delivery.....	14
1.9.3	Oxytocin-conjugates for nose to brain delivery.....	14
1.10	Plan of Work.....	15
1.10.1	Development and Characterization of Ready to Infuse Formulations.....	15
1.10.2	Development and Characterization of Nano-formulations for Nose to Brain Delivery.....	15
1.10.3	Synthesis and Characterization of Oxytocin Conjugate for Nose to Brain Delivery.....	15

CHAPTER-2

2. LITERATURE REVIEW	20
2.1 PEPTIDE THERAPEUTICS	20
2.2 CHALLENGES OF PEPTIDES AS THERAPEUTIC AGENTS.....	21
2.3 DRUG PROFILE	23
2.3.1 Oxytocin.....	23
2.3.1.1 Functions of OXT	23
2.3.1.2 Pharmacology and Biochemistry	24
2.3.1.3 Clinical usage of OXT in Gynaecology and obstetrics: a life-saving drug in women.....	25
2.3.1.4 Cardiovascular protective properties	31
2.3.1.5 Oxytocin in Brain Disorders	31
2.3.1.6 Neuropsychiatric disorders	33
2.3.1.7 Neurodegenerative disorders	37
2.3.1.8 Clinical Studies in Neurological Disorders.....	40
2.3.2 Vasopressin.....	41
2.3.2.1 Chemistry, biogenesis and pharmacology	45
2.3.2.2 Pharmacokinetics of Vasopressin	47
2.3.2.3 Role of V1 and V2 receptors	47
2.3.2.4 Cerebrospinal fluid and Vasopressin	51
2.3.2.5 Vasopressin in neurological disorders: Clinical and preclinical studies of Vasopressin.....	54
2.3.3 Angiotensin.....	64
2.3.3.1 Pharmacology of Angiotensin.....	65
2.3.3.2 Pharmacokinetics of Angiotensin-II	69
2.3.3.3 Preclinical applications of RAS in neurological disorders	70
2.3.3.4 Clinical applications of RAS in neurological disorders.....	76
2.4 RECENT ADVANCEMENT FOR ENHANCED NEURONAL DELIVERY USING VARIOUS CARRIER SYSTEMS	84
2.4.1 Recent therapeutic strategies for peptide delivery.....	85
2.4.1.1 Nanocarriers-based delivery approach.....	86
2.4.1.2 Nanocarriers mediated delivery of peptide to brain.....	91
2.4.2 Ready to Infuse (RTI) formulation	101
2.4.3 Conjugation of peptide molecules to enhance their pharmacokinetics and pharmacodynamic attributes	102

CHAPTER-3

3. INTRODUCTION	132
3.1 Materials and Instruments.....	132
3.2 Instruments.....	139
3.3 High Performance Liquid Chromatographic Method for Oxytocin	139
3.3.1. Instrumentation and chromatographic conditions.....	139
3.3.2. HPLC method validation	141
3.3.3. Results and Discussion	143
3.3.3.1 HPLC method development.....	143
3.3.3.2 HPLC method validation	143
3.4 High Performance Liquid Chromatographic Method for Vasopressin.....	147
3.4.1 Instrumentation and chromatographic conditions.....	147
3.4.2 HPLC method validation	148
3.4.3 Results and Discussion	150
3.4.3.1 HPLC method Development.....	150
3.4.3.2 HPLC method validation	150
3.5 High performance Liquid chromatographic method for Angiotensin II.....	154
3.5.1 Instrumentation and chromatographic conditions.....	154
3.5.2 HPLC method validation	154
3.5.3 Results and Discussion	155
3.5.3.1 HPLC method Development.....	155
3.5.3.2 HPLC method validation	156

CHAPTER-4

4.1 Introduction.....	162
4.2 Materials and Instruments.....	162
4.3 Formulation Development	164
4.3.1 Development and Optimization of Ready to Infuse formulation of Oxytocin 164	
4.3.1.1 Manufacturing procedure.....	164
4.3.1.2 Preliminary Feasibility and Developmental trials.....	165
4.3.1.3 Selection of Osmogens	167
4.3.1.4 Optimization of selected excipients	169
4.3.1.5 pH Stability Study.....	171
4.3.1.6 Sterilization method selection for Oxytocin RTI.....	174
4.3.1.7 Evaluation of optimized formulation prepared by aseptic filtration method... 176	
4.3.1.8 Temperature cycling study.....	179
4.3.1.9 Oxygen Sensitivity Study	180
4.3.1.10 Photostability study for Oxytocin RTI.....	182

4.3.1.11 Hold time/Manufacturing vessel compatibility	183
4.3.1.12 Filter membrane compatibility study.....	185
4.3.1.13 Stability study of optimized RTI formulation of Oxytocin.....	186
4.3.1.14 Stability study with higher strength.....	190
4.3.1.15 Stability Study Report at $5 \pm 3^\circ\text{C}$ & $25^\circ\text{C}/40\%\text{RH}$	193
4.3.1.16.Stability Study: Assay vs Months	194
4.3.2 Development and Optimization of Ready to Infuse formulation of Vasopressin	203
4.3.2.1.Formulation development for Selection of Osmogens	203
4.3.2.2.pH Stability Study.....	205
4.3.2.3.Manufacturing Process for RTI formulation of Vasopressin.....	206
4.3.2.4.Sterilization method selection for Vasopressin RTI	207
4.3.2.5.Photostability study for Vasopressin RTI.....	207
4.3.2.6.Stability study of Vasopressin RTI formulation	208
4.3.2.7.Stability Study Report at $5 \pm 3^\circ\text{C}$ & $25^\circ\text{C}/40\%\text{RH}$ for final formulation as per ICH Q1E	214
4.3.2.8.Stability Report at $5 \pm 3^\circ\text{C}$ & $25^\circ\text{C}/40\%\text{RH}$	224
2.3.3 Development and Optimization of Ready to Infuse formulation of Angiotensin-II	224
4.3.3.1 Formulation development.....	224
4.3.3.3 pH Stability Study.....	225
4.3.3.4 Sterilization method selection for Angiotensin-II RTI.....	227
4.3.3.5 Photostability study for Angiotensin-II RTI.....	227
4.3.3.6 Manufacturing process and Stability study for RTI formulation of Angiotensin-II	228
4.3.3.7 Stability report at $5 \pm 3^\circ\text{C}$ & $25^\circ\text{C}/40\%\text{RH}$	242
4.4 <i>In vitro</i> Biological Reactivity of Final RTI formulations of Oxytocin, Vasopressin and Angiotensin-II by Agarose Diffusion Assay.....	242

CHAPTER-5

5.1 Background	247
5.2 Materials and Instruments.....	249
5.3 Preparation, characterization and evaluation of drug loaded nanovesicles	251
5.3.2 Methodology for characterization of nanovesicles	252
5.3.2.1 Micromeritics of nanovesicles	252
5.3.2.2 Percentage drug entrapment (%EE).....	253
5.3.3 Optimization of nanovesicles for Oxytocin	253

5.3.3.1 Optimization of lipid ratio	253
5.3.3.2 Optimization of process variables.....	254
5.3.4 Optimization of nanovesicles for vasopressin	255
5.3.4.1 Optimization of lipids ratio.....	255
5.3.4.2 Optimization of process variables.....	255
5.3.5 Stability of nanovesicles formulations.....	255
5.3.6 In vitro cell line study	256
5.3.6.1 % Cell viability and Cell uptake study on SH-SY5Y cells.....	256
5.3.6.2 Evaluation on monocytic cells (THP-I)	259
5.3.7 Neurological activities of developed formulations in experimental animals...	262
5.3.7.1 Rationale for In vivo studies	262
5.3.7.2 Morris water maze test (MWM)	263
5.3.7.3 Brain Hippocampus histopathological evaluation	264
5.3.7.4 Gene Expression Studies.....	264
5.3.7.5 Biochemical analysis	265
5.4. Results and discussion	267
5.4.1. Fabrication of Nanovesicles for Oxytocin and Vasopressin.....	267
5.4.2. Optimization of nanovesicles for oxytocin and vasopressin.....	267
5.4.2.1. Oxytocin loaded nanovesicles.....	267
5.4.2.2. Vasopressin loaded nanovesicles	269
5.4.3. Physicochemical attributes of optimised formulations	269
5.4.4. Stability study of nanovesicles formulations	271
5.4.4.1. Oxytocin-Loaded Nanovesicles	271
5.4.4.2. Vasopressin-Loaded Nanovesicles	272
5.4.5. In vitro cell line study	273
5.4.5.1. Evaluation on SH-SY5Y neuro cells	273
5.4.5.2. Evaluation on monocytic cells (THP-I)	284
5.4.5.3. Neurological effects of developed formulations in experimental animals	281

CHAPTER-6

6.AEEA-OXYTOCIN CONJUGATION FOR NOSE TO BRAIN DELIVERY	296
6.1 Background.....	296
6.2 Materials and Instruments.....	296
6.3 Synthesis and Characterization of AEEA-Oxytocin.....	298
6.3.1 Synthesis of AEEA-Oxytocin.....	298
6.3.2 Characterization	300
6.4 In vitro cell line study	301
6.4.1 Evaluation on SH-SY5Y neuro cells	301
6.4.1.1 % Cell viability and biocompatibility	301
6.4.1.2 In vitro cell permeation study: Quantitative	302
6.4.1.3 Cell permeation study (Cell uptake)	302
6.4.1.4 Cell apoptosis assay	303
6.4.1.5 Reactive Oxygen Species (ROS) Assay	304
6.4.2 Evaluation on monocytic cells (THP-1)	304
6.4.2.1 Analysis using genomic microarrays (qRT-PCR)	304
6.4.2.2 Immunofluorescence assay (IFA).....	304
6.5 Neurological activities in experimental animals.....	304
6.5.1 Methodology for Pharmacodynamics studies.....	304
6.5.2 Morris water maze (MWM) test	305
6.5.3 Brain Hippocampus histopathological evaluation	306
6.5.4 Gene Expression and Biochemical Studies.....	306
6.5.5 Biochemical analysis	307
6.6 Results and discussion	307
6.6.1 Synthesis and characterization of AEEA-Oxytocin.....	307
6.6.2 In vitro cell line study	312
6.6.2.1 Evaluation on SH-SY5Y neuro cells	312

6.6.2.2 Evaluation on monocytic cells (THP-1)	318
6.6.3 Neurological effects in experimental animals.....	320
6.6.3.1 Morris water maze test.....	320
6.6.3.2 Gene expression	320
6.6.3.3 Biochemical estimations	322
6.6.3.4 Brain Histopathology examinations.....	323

CHAPTER-7

7.SUMMARY AND CONCLUSIONS	327
7.1 SUMMARY	327
7.1.1 Analytical method development of oxytocin, vasopressin and angiotensin	328
7.1.2 Development of RTI dosage	330
7.1.2.1 Development of RTI dosage form for oxytocin.....	330
7.1.2.2 Development of RTI dosage form for vasopressin	333
7.1.2.3 Development of RTI dosage form for angiotensin	335
7.1.3 Development of lipidic nanovesicles for nose to brain delivery.....	336
7.1.3.1 Formulation and characterization	336
7.1.3.2 Evaluation on monocytic cells (THP-I)	337
7.1.3.3 Ex vivo evaluation on SH-SY5Y	338
7.1.3.4 Evaluation in AD induced animal model.....	339
7.1.4 AEEA-Oxytocin Conjugates for nose to brain delivery	342
7.1.4.1 Synthesis and Characterization of AEEA-Oxytocin.....	342
7.1.4.2 Evaluation on SH-SY5Y neuro cells	343
7.1.4.3 Evaluation of AEEA- OXT on monocytic cells (THP-I).....	345
7.1.4.4 Neurological effects in experimental animals.....	346
7.2 CONCLUSIONS.....	347

ANNEXURE-I (List of publications)	348
--	------------

LIST OF FIGURES OF THE THESIS

CHAPTER-1

Figure 1.1: A summary of the design process for peptide therapeutics and their associated delivery systems.....3

Figure 1.2: Various nanocarriers for delivery of peptides12

CHAPTER-2

Figure 2.1: Various challenges of delivering macromolecules..... 22

Figure 2.2: A) Chemistry of vasopressin and B) site of its release from the pituitary gland.....48

Figure 2.3: Signalling mechanism of Angiotensin in body 67

CHAPTER-3

Figure 3.1: HPLC chromatogram for Oxytocin standard and samples.....144

Figure 3.2: Linearity plot of Oxytocin 145

Figure 3.3: HPLC chromatogram for vasopressin standard..... 151

Figure 3.4: Linearity plot of vasopressin 152

Figure 3.5: Blank-diluent chromatogram of Angiotensin-II standard 156

Figure 3.6: Blank-diluent chromatogram of Angiotensin-II API 157

Figure 3.7: Linearity plot of angiotensin II..... 157

CHAPTER-4

Figure 4.1: Assay of Oxytocin in RTI formulation at different pH at Initial level and after 3M at 25 °C/40% RH. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 172

Figure 4.2: Osmolarity of Oxytocin RTI formulation at different pH at Initial level and after 3M at 25 °C/40% RH. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 172

Figure 4.3: Decision tree for sterilization choices for aqueous based products..... 175

Figure 4.4: Short term Stability Plot of Assay (mean) at different conditions and at different time point for optimized Oxytocin formulation (Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 177

Figure 4.5: Short term stability plot of pH at different conditions and at different time point. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 177

Figure 4.6: Short term stability plot of osmolarity at different conditions and at different time point. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 179

Figure 4.7: Assay of Oxytocin in RTI formulation after different freeze (-20 °C) thaw (+40 °C) cycles. Graph presents mean of individual value. Red line in graph presents upper control limit (UCL) and lower control limit (LCL) 180

Figure 4.8: Sensitivity to gas: Assay of Oxytocin in RTI formulation after purging with different gases. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 182

Figure 4.9: Assay of Oxytocin at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control 189

Figure 4.10: pH of Oxytocin formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 189

Figure 4.11: Osmolarity of Oxytocin formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 190

Figure 4.12: Assay of Oxytocin in final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 191

Figure 4.13: pH of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 191

Figure 4.14: Osmolarity of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 193

Figure 4.15: Shelf Life Plot for All Batches 194

Figure 4.16: Shelf Life Plot for All Batches 195

Figure 4.17: Shelf Life Plot for Batch 0.02 195

Figure 4.18: Shelf Life Plot for Batch 0.08 196

Figure 4.19: Shelf Life Plot for All Batches 196

Figure 4.20: Shelf Life Plot for All Batches 197

Figure 4.21: Shelf Life Plot for All Batches 197

Figure 4.22: Assay of Vasopressin at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 209

Figure 4.23: pH of vasopressin formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 210

Figure 4.24: Osmolarity of vasopressin formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit. 210

Figure 4.25: Assay of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 213

Figure 4.26: pH of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 213

Figure 4.27: Osmolality of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit..... 214

Figure 4.28: Shelf Life Plot for Batch 1 215

Figure 4.29: Shelf Life Plot for Batch 2 215

Figure 4.30: Shelf Life Plot for Batch 1 & 2 216

Figure 4.31: Shelf Life Plot for Batch 1 216

Figure 4.32: Shelf Life Plot for Batch 2 217

Figure 4.33: Shelf Life Plot for Batch 1 & 2 217

Figure 4.34: Shelf Life Plot for All Batches 218

Figure 4.35: Shelf Life Plot for Batch 1 218

Figure 4.36: Shelf Life Plot Batch 2 219

Figure 4.37: Shelf Life Plot for All Batches 219

Figure 4.38: Shelf Life Plot for Batch 1 220

Figure 4.39: Shelf Life Plot for Batch 2 220

Figure 4.40: Shelf Life Plot for All Batches	221
Figure 4.41: Shelf Life Plot for All Batch	221
Figure 4.42: Assay of Angiotensin-II at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit.....	229
Figure 4.43: pH of Angiotensin-II formulation at different stability conditions and time points.....	230
Figure 4.44: Osmolarity of Angiotensin-II formulation at different stability conditions and time points: Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit.	232
Figure 4.45: Assay of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit.....	232
Figure 4.46: pH of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL (upper control limit) and lower control limit.....	233
Figure 4.47: Osmolality of final formulation at different stability conditions and time points. Graph presents mean of individual value. Red line in graph presents UCL and LCL.	233
Figure 4.48: Shelf Life Plot for Batch 1 & 2	236
Figure 4.49 : Shelf Life Plot for All Batches	236
Figure 4.50: Shelf Life Plot for All Batches	237
Figure 4.51: Shelf Life Plot for Batch 1	237
Figure 4.52: Shelf Life Plot for Batch 2	238

Figure 4.53: Shelf Life Plot for Batch Shelf Life Plot for All Batches 238

Figure 4.54: Shelf Life Plot for Batch Shelf Life Plot for All Batches 239

Figure 4.55: Shelf Life Plot for Batch Shelf Life Plot for All Batches 239

Figure 4.56: Final all three Ready to use formulations..... 243

CHAPTER-5

Figure 5.1: Schematic presentation of fabrication of nanovesicles 254

Figure 5.2: Graph of Particle size analysis (A), and HR-TEM image (B) of oxytocin loaded nanovesicles and vasopressin loaded nanovesicles respectively. 271

Figure 5.3: % Cell viability after the exposure of different formulations (plain and drug-loaded) after 24 h, 48 h & 72 h incubation 274

Figure 5.4: Morphological observation of SH-SY5Y cells treated with High dose of vasopressin, oxytocin, vasopressin loaded nanovesicles and oxytocin loaded nanovesicles for 48 h at 20× magnification. 275

Figure 5.5: Cell uptake of SH-SY5Y cells treated with High dose of vasopressin, oxytocin, vasopressin loaded nanovesicles and oxytocin loaded nanovesicles for 48 h at 20× magnification. 275

Figure 5.6: ROS generation of SH-SY5Y cells treated with control, Oxytocin, vasopressin, OXT-Nanovesicles and Vaso-nanovesicles at 100µg/mL for 48 h at 20× magnification. 277

Figure 5.7: Acridine orange/Ethidium bromide dual staining studies of control, Vasopressin, vasopressin loaded nanovesicles, oxytocin and oxytocin loaded nanovesicles at high dose in SH-SY5Y cells for 48 h at 20× magnification. 278

Figure 5.8: Determination of transcriptional gene expression of inflammatory, signalling and apoptotic markers 279

Figure 5.9: Expression of FOXO-1 gene following the LPS after various formulations treatment 280

Figure 5.10: Oxytocin loaded nanovesicles treated cells were lysed, and NfκB and Bim proteins were detected by the immunoblotting technique 281

Figure 5.11: Pharmacological evaluation of formulations in Balb/C mice by Morris maze water studies. free oxytocin solution and oxytocin encapsulated nanovesicles administered via i.n. & i.v. route. Data are represented for control (Ctrl), scopolamine treated (SCP), oxytocin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), oxytocin (i.n.) and oxytocin (i.v.). Figure A for acquisition trials, while figure B represents the time in seconds required by animal to reach the hidden platform. 282

Figure 5.12: Gene expression of brain with different treatment groups. Data are represented for control (Ctrl), scopolamine treated (SCP), oxytocin loaded nanovesicles intranasal (IN) and intravenous (IV), oxytocin (IN) and oxytocin (IV)..... 283

Figure 5.13: Biochemical estimation of brain homogenates with different treatment groups. Data are represented for control (Ctrl), scopolamine treated (SCP), oxytocin loaded nanovesicles intranasal (IN) and intravenous (IV), oxytocin (IN) and oxytocin (IV)..... 284

Figure 5.14: Images of histopathology evaluation of brain Hippocampus of Balb/C with scale 50 µm. Animals treated with free oxytocin solution and oxytocin encapsulated nanovesicles administered via i.n. & i.v. route. Data are represented for control (nanovesicles placebo), scopolamine treated (SCP), oxytocin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), oxytocin (i.n.) and oxytocin (i.v.)..... 286

Figure 5.15: Pharmacological evaluation of formulations in Balb/C mice by Morris maze water studies. free vasopressin solution and vasopressin encapsulated nanovesicles administered via i.n. & i.v. route. Data are represented for control (Ctrl), scopolamine treated (SCP), vasopressin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), vasopressin (i.n.) and vasopressin (i.v.). Figure A for acquisition trials, while figure B represents the time spent by animal to reach the hidden platform in..... 287

Figure 5.16: Gene expression level of brain samples. Data are represented for control (Ctrl), scopolamine treated (SCP), Vasopressin-loaded Nanovesicles intranasal (i.n.) and intravenous (i.v.), vasopressin (i.n.) and vasopressin (i.v.) 289

Figure 5.17: Biochemical estimation of brain homogenates. Data are represented for control (Ctrl), scopolamine treated (SCP), vasopressin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), vasopressin (i.n.) and vasopressin (i.v.)..... 290

Figure 5.18: Images of histopathology evaluation of brain Hippocampus of Balb/C with scale 50 μ m. Animals treated with free vasopressin solution and vasopressin encapsulated nanovesicles administered via i.n. & i.v. route. Data are represented for control (Naïve), scopolamine treated (SCP), SCP+vasopressin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), SCP+ vasopressin (i.n.), and SCP+ Vasopressin (i.v.).scopolamine treated (SCP), SCP+vasopressin loaded nanovesicles intranasal (i.n) and intravenous (i.v.), SCP+ vasopressin (i.n.), and SCP+ Vasopressin (i.v.)..... 291

CHAPTER-6

Figure 6.1: Structure of prepared AEEA-oxytocin conjugate 298

Figure 6.2: Schematic presentation of synthesis of NH₂-AEEA-OXYTOCIN 299

Figure 6.3: FT-IR Spectra of AEEA-Oxytocin..... 309

Figure 6.4: NMR spectra of oxytocin & AEEA-Oxytocin 310

Figure 6.5: Mass spectra of Oxytocin and direct mass spectra of AEEA-oxytocin 311

Figure 6.6: % Cell viability after the exposure of oxytocin and AEEA-oxytocin after 24 h, 48 h & 72 h incubation..... 312

Figure 6.7: % of Cell uptake after the exposure of oxytocin and AEEA-oxytocin after 1 h, 2 h & 3 h incubation (n=3)..... 313

Figure 6.8: Morphological observation of SH-SY5Y cells treated with high dose (100 μ g/mL) of oxytocin and AEEA-Oxytocin for 48 h at 20 \times magnification 314

Figure 6.9: Cell uptake of SH-SY5Y cells control, treated with High dose (100 μ g/mL) of oxytocin and AEEA-oxytocin for 48 h at 20 \times magnification..... 315

Figure 6.10: ROS generation of SH-SY5Y cells treated with control, oxytocin and AEEA-oxytocin at 100 µg/mL for 48 h at 20× magnification..... 316

Figure 6.11: Acridine orange/Ethidium bromide dual staining studies of control, oxytocin and AEEA-oxytocin at high dose in SH-SY5Y cells for 48 h at 20× magnification..... 317

Figure 6.12: Determination of transcriptional gene expression of inflammatory, signalling and apoptotic markers 318

Figure 6.13: Expression of FOXO-1 gene following the LPS after various formulations treatment 319

Figure 6.14: Pharmacological evaluation of formulations in Balb/C mice by MWM studies: free oxytocin solution and AEEA-oxytocin solution administered via i.n. route. Data are represented for control (Ctrl), scopolamine treated (SCP), SCP + oxytocin (i.n) and SCP + AEEA-oxytocin (i.n). Figure A for acquisition trials, while figure B represents time required in seconds by mice to reach the hidden platform 320

Figure 6.15: Gene expression of isolated brain. Data are represented for control (Ctrl), scopolamine treated (SCP), SCP + oxytocin (i.n) and SCP + AEEA-oxytocin (i.n)..... 322

Figure 6.16: Biochemical estimation of homogenated brain. Data are represented for control (Ctrl), scopolamine treated (SCP), SCP + oxytocin (i.n) and SCP + AEEA-oxytocin (i.n)..... 323

Figure 6.17: Images of histopathology evaluation of brain Hippocampus of Balb/C with scale 50 µm. Animals treated with free oxytocin and AEE-Oxytocin solution via i.n. route. Data are represented for control, scopolamine treated (SCP), SCP+OXT intranasal (i.n), SCP+AEEA-OXT (i.n.) 324

LIST OF TABLES OF THE THESIS

CHAPTER-1

Table 1.1: Comparison of RTI dosage form and small volume injections9

CHAPTER-2

Table 2.1: Dose of OXT in human.....26

Table 2.2: Dose & uses of different OXT injections in human in various regulatory markets27

Table 2.3: OXT to manage neurological ailments: Clinical summary42

Table 2.4: Patent insights on use of OXT in neurological disorders44

Table 2.5: Clinical and preclinical studies of Vasopressin56

Table 2.6: Preclinical studies of Angiotensin for neurological disorders71

Table 2.7: Clinical studies of Angiotensin for neurological disorders79

Table 2.8: Recent advancements in nanocarriers mediated delivery of biomacromolecules.92

Table 2.9: Nanotechnologies used so far to target the brain and treat neurological conditions99

CHAPTER-3

Table 3.1: Raw materials, chemicals and reagents employed in the current research work133

Table 3.2: Details of various instruments employed during the current research work .139

Table 3.3: Chromatographic conditions for oxytocin140

Table 3.4: Peak areas at different concentrations of OXT for constructing the calibration plot144

Table 3.5: Accuracy in measuring a known concentration of OXT146

Table 3.6: Validation for intra- and inter-day precision	146
Table 3.7: Chromatographic conditions.....	148
Table 3.8: Peak areas at different concentrations of Vasopressin for constructing the calibration plot	151
Table 3.9: Accuracy in measuring a known concentration of vasopressin.....	153
Table 3.10: Validation for intra- and inter-day precision	153
Table 3.11: Chromatographic condition for Angiotensin-II	155
Table 3.12: Peak areas at different concentrations of Angiotensin for constructing the calibration plot	157
Table 3.13: Accuracy in measuring a known concentration of Angiotensin II	158
Table 3.14: Validation for intra- and inter-day precision	159

CHAPTER-4

Table 4.1: Raw materials, chemicals and reagents employed in the current research work.....	162
Table 4.2: Details of various instruments employed during current research work	163
Table 4.3: Details of Packaging materials used in RTI formulation.....	165
Table 4.4 : Initial data of various preliminary developmental trials	165
Table 4.5: Initial data of various preliminary development trials for selection of Osmogens for Oxytocin	167
Table 4.6: Development trials for selection of excipients for Oxytocin RTI	169
Table 4.7: pH study data of experimental trials	173
Table 4.8: Effect of sterilization process on the Oxytocin RTI formulation by autoclaving.....	176
Table 4.9: Short term stability data of optimized Oxytocin RTI formulation	178

Table 4.10: Experimental data of freeze thaw cycle study	180
Table 4.11: Effect of different gases on Oxytocin assay	181
Table 4.12: Effect of light on assay of Oxytocin	183
Table 4.13: Stainless steel (SS316L) compatibility data at room temperature (~20-25°C).....	184
Table 4.14: Filter membrane compatibility data at room temperature (~20-25°C)	185
Table 4.15: Stability data of Oxytocin injection RTI 0.02 IU/mL.....	188
Table 4.16: Stability data of Oxytocin injection 0.08 IU/mL	192
Table 4.17: Drug Product CQAs.....	199
Table 4.18: Shelf-life estimation of developmental batches of Oxytocin RTI @ 25°C/40%RH	201
Table 4.19: Shelf-life estimation of developmental batches of Oxytocin RTI @ 5 ± 3°C.....	202
Table 4.20: Development trials with different osmogens for Vasopressin RTI formulation.....	203
Table 4.21: Trials with HPβCD for Vasopressin RTI formulation.....	205
Table 4.22: pH study data of experimental trials (Vasopressin).....	205
Table 4.23: Effect of sterilization process on the Vasopressin RTI formulation.....	207
Table 4.24: Effect of light on Vasopressin RTI.....	208
Table 4.25: Stability of formulations in infusion bags at initial stage and after 12M at different temperature conditions (Batch 1)	211
Table 4.26: Stability of formulations in infusion bags at initial stage and after 12M at different temperature conditions (Batch 2)	212
Table 4.27: Shelf life estimation of developmental batches of Vasopressin RTI @ 25°C/40%RH	222

Table 4.28: Shelf life estimation of developmental batches of Vasopressin RTI @5 ± 3°C.223

Table 4.29: Development trials with different osmogens for angiotensin RTI formulation.....224

Table 4.30: pH study data of experimental trials (Angiotensin).....226

Table 4.31: Effect of sterilization process on the Angiotensin-II RTI formulation.....227

Table 4.32: Effect of light on Angiotensin-II RTI.....227

Table 4.33: Stability of final formulation in infusion bags at initial stage and after 12M at different temperature conditions231

Table 4.34: Stability of final formulation in infusion bags at initial stage and after 12M at different temperature conditions (Batch 2)234

Table 4.35: Shelf life estimation of developmental batches of Angiotensin II RTI @ 25°C/40%RH240

Table 4.36: Shelf life estimation of developmental batches of Angiotensin II RTI @ 5 ± 3°C241

Table 4.37: Reactivity grades for agarose diffusion test.....243

Table 4.38: Outcomes of Biological reactivity study244

CHAPTER-5

Table 5.1: List of raw materials and chemicals used in the current research work249

Table 5.2: Details of various instruments employed during the current research work .250

Table 5.3: The information of the primer sequences for all genes260

Table 5.4: Primers of Genes for qRT-PCR with their role in brain265

Table 5.5: Optimization of ratio of lipids for oxytocin loaded nanovesicles formulation.....268

Table 5.6: Optimization with respect to stirring speed for oxytocin loaded nanovesicles formulation	268
Table 5.7: Optimization of stirring time for oxytocin loaded nanovesicles formulation	268
Table 5.8: Optimized parameters for oxytocin loaded nanovesicles formulation	269
Table 5.9: Optimization with respect to ratio of lipids used cholesterol ratio for vasopressin loaded nanovesicles formulation	270
Table 5.10: Optimization with respect to stirring speed for vasopressin loaded nanovesicles formulation	270
Table 5.11: Optimization of stirring time for vasopressin loaded nanovesicles formulation.....	270
Table 5.12: Optimized parameters for Nanovesicles for Vasopressin	271
Table 5.13: Physicochemical attributes of optimised Oxytocin and Vasopressin loaded nanovesicles	271
Table 5.14: Stability data of Oxytocin loaded nanovesicles	272
Table 5.15: Stability data of Nanovesicles for Vasopressin	273

CHAPTER-6

Table 6.1: List of raw materials and chemicals used in the current research work.....	296
Table 6.2: Details of various instruments employed during the current research work.....	297
Table 6.3: Primers of Genes for qRT-PCR with their role in brain	307
Table 6.4: Observations from NMR spectra of Oxytocin	307
Table 6.5: Observations from NMR spectra of AEEA-Oxytocin	308
Table 6.6: Major Peaks observed in MS spectra.....	309

CONTENTS OF EXECUTIVE SUMMARY

1. SUMMARY.....	1
1.1 Introduction	1
1.2 Analytical method development of oxytocin, vasopressin and angiotensin	2
1.3 Development of RTI dosage	4
1.3.1 Development of RTI dosage form for oxytocin	4
1.3.2 Development of RTI dosage form for vasopressin	7
1.3.3 Development of RTI dosage form for angiotensin.....	9
1.4 Development of lipidic nanovesicles for nose to brain delivery	11
1.4.1 Formulation and characterization.....	11
1.4.2 Evaluation on monocytic cells (THP-I)	12
1.4.3 <i>Ex vivo</i> evaluation on SH-SY5Y.....	13
1.4.4 Evaluation in AD induced animal model	14
1.5 AEEA-Oxytocin Conjugates for nose to brain delivery.....	18
1.5.1 Synthesis and Characterization of AEEA-Oxytocin	18
1.5.2 Evaluation on SH-SY5Y neuro cells.....	19
1.5.3 Evaluation of AEEA- OXT on monocytic cells (THP-I).....	21
1.5.4 Neurological effects in experimental animals.....	22
2. CONCLUSIONS	23
3. FUTURE PERSPECTIVES.....	24
4. REFERENCES	25

1. SUMMARY

1.1 Introduction

The current thesis, titled “Design, Development and Characterization of Drug Delivery System for Bioactive(s),” is focused on enhancing the efficacy of selected bioactive compounds through two innovative dosage forms: The Ready to Infuse (RTI) dosage form and lipidic nanovesicles. These approaches are tailored for specific medical indications, employing distinct routes of administration. In this investigation, the bio actives, oxytocin (OXT), vasopressin, and angiotensin have been chosen for their potential therapeutic benefits, with a particular emphasis on the development of RTI formulations. Furthermore, nanovesicle technology is utilized to facilitate the delivery of OXT and vasopressin through the nasal route for targeting the brain directly.

RTI delivery system: The limitations of injections and lyophilized powder for injections which need to be diluted before administration underscore the urgent need for a formulation that is ready for immediate use, enabling healthcare professionals to administer it directly to patients without delay. Additionally, the process of manufacturing injectable drugs that are sensitive to both oxygen and light introduces complexities when utilizing plastic infusion bags. These bags possess a semipermeable nature that can react with atmospheric oxygen during the manufacturing stages, which extends up until the final packing of the product [1]. By acknowledging the challenges associated with dilution and stability, this research aimed to design, develop, and optimize highly effective RTI delivery systems for the bioactive peptides OXT, Vasopressin, and Angiotensin-II. By doing so, the study sought to resolve the various issues tied to these selected peptides. The adoption of the RTI method will facilitate the production of injections with lower concentrations of active ingredients, ultimately enhancing patient compliance and safety. Ensuring patient safety is paramount in this context, as the RTI approach uniquely minimizes the risk of dosing errors to zero while also significantly reducing the chances of cross-contamination.

The proposed “Ready to Infuse” dosage form is anticipated to be a ground breaking solution, characterized by a novel pharmacological strategy for administration, innovative formulations, and unique dosage forms that are well-suited for intellectual property protection and commercialization. As for the lipidic nanovesicles: This formulation development area is of

immense significance, leveraging advanced principles of drug delivery systems (DDSs) to implement improvements without altering the inherent chemistry of the drugs involved.

Nanovesicles systems:

The rapidly developing nanotechnology has provided new possibilities for transporting therapeutic drugs across the BBB to treat brain diseases. Considering the biocompatibility, safety, and complexity of the production process, nanovesicles are superior among all synthetic nanocarriers. Vesicles are aqueous core containing nanostructures enclosed by a lipid/polymer bilayer encapsulating an active ingredient or therapeutic molecule [2]. Nanovesicular systems bridge gap between hydrophilic and hydrophobic heterogeneity in one drug delivery system. Either hydrophilic drug or lipophilic one can be encapsulated in vesicles, even both of them simultaneously [3]. Nanovesicles can contain a large range of proteins, lipids, and nucleic acid species. Encapsulation of a drug into vesicles can markedly modify its plasma half-life, site, specificity and bioavailability. Therefore, Nanovesicles are considered to be potential biological drug-delivery systems that can stably deliver their cargo into targeted cells [4].

Conjugation of AEEA with OXT: Presently, chemical modification is recognized as a powerful strategy for developing therapeutic peptide analogues with specifically targeted and desirable structures. Among the selected bio actives in this research, OXT has been identified as a model molecule, primarily due to its very short half-life in circulation (ranging from approximately 4 to 10 minutes). This research aimed to significantly enhance the retention time of OXT within the body while simultaneously improving its ability to permeate the blood-brain barrier (BBB). This objective was accomplished through the conjugation of 2-(2-(2-Aminoethoxy) ethoxy) acetic acid (AEEA) with one of the amino acids present in the OXT structure, thus aimed at enhancing its biopharmaceutical properties and therapeutic efficacy [5].

A brief summary of the entire work, results and conclusions drawn from it, are presented here as under:

1.2 Analytical method development of oxytocin, vasopressin and angiotensin

High Performance Liquid Chromatography (HPLC) is one of the most important tools of analytical chemistry [6]. In the modern pharmaceutical industry, HPLC is the major and

integral analytical tool applied in all stages of drug discovery, development, and production [7]. HPLC is the method of choice for checking peak purity of new chemical entities, monitoring reaction changes in synthetic procedures or scale up, evaluating new formulations and carrying out quality control / assurance of the final drug products [8]. The Goal of HPLC method is to separate and quantify the main drug, any reaction impurities, all available synthetic intermediates and any degradants [9]. Any sample that can dissolve in a solvent can be used with an HPLC device to identify, separate, measure the compounds that are present. HPLC is the most accurate analytical methods widely used for the quantitative as well as qualitative analysis of drug product and used for determining drug product stability [10]. In HPLC, a sample solution is pumped into a porous column (the stationary phase), and a liquid phase (the mobile phase) is pushed through the column at high pressure. The principle of separation followed is the adsorption of solute on stationary phase based on its affinity towards stationary phase. (HPLC) represents an approach which may directly address the shortcomings of the bioanalytical methods and conveniently sidesteps the concomitant ethical issues [11, 12].

The analytical framework for OXT has been discussed, highlighting the necessity for further validation and establishment of its measurements across various dosage forms for diverse studies. A novel and efficient Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) method was successfully developed, adhering to the guidelines set forth by the International Conference on Harmonization (ICH). This method was routinely employed to quantitatively estimate OXT during the research studies. The calibration curve achieved remarkable linearity, exhibiting an r^2 value of 0.9931 within a concentration range of 0.02 to 0.2 $\mu\text{g/mL}$. The limits of detection (LOD) and quantification (LOQ) for OXT were determined to be 0.00195 $\mu\text{g/mL}$ and 0.00558 $\mu\text{g/mL}$, respectively. This suggests that the developed HPLC method is capable of effectively detecting and quantifying OXT even at remarkably low concentrations. The findings confirmed that the RP-HPLC method demonstrated high resolution, accuracy, and precision, making it suitable for the identification and quantification of OXT in any dosage form.

To ascertain the presence and concentration of vasopressin, significant efforts were made to develop an analytical technique based on Ultraviolet (UV) and HPLC methodologies. The HPLC analytical approach underwent a rigorous validation process, focusing on parameters

such as linearity, accuracy, precision, LOD, and LOQ. Within the tested concentration range of 0.5 to 50 µg/mL, the calibration curves consistently displayed linearity with an impressive r^2 value of 0.999. For the assessment of percent accuracy, vasopressin was analysed at several concentrations, namely, 5, 20.0, and 50.0 µg/mL. The data reflected that the analytical method exhibited a high degree of repeatability, indicated by the corresponding percent relative standard deviation (% RSD) values, which ranged from 0.78 to 0.97 for intra-day studies and from 0.88 to 1.19 for inter-day studies. All values fell well within the permissible RSD threshold of less than 2%, demonstrating that the developed method possessed adequate precision and repeatability for estimating vasopressin. Moreover, the LOD was determined to be 0.049 µg/mL, while the LOQ was found to be 0.147 µg/mL, affirming that even low concentrations of vasopressin could be reliably detected and quantified using this validated HPLC method.

In an additional effort to evaluate the presence and concentration of angiotensin, HPLC technique was employed. The analytical method for angiotensin was similarly validated for parameters such as linearity, accuracy, precision, LOD, and LOQ. Across the measured concentration range of 2 to 20 µg/mL, the calibration curves yielded a strong linearity, achieving an r^2 value of 0.9986. For accuracy estimation, angiotensin was assessed at varying drug concentrations including 2, 10.0, and 20.0 µg/mL. The results indicated that the analytical method demonstrated sufficient repeatability, as evidenced by the % RSD values ranging from 0.41 to 0.48 for intra-day studies and from 0.1 to 0.78 for inter-day studies. All obtained values remained comfortably within the acceptable limits of RSD less than 2%, reaffirming that the method showcased the necessary precision and repeatability for estimating angiotensin levels. The LOD for angiotensin was measured at 0.09 µg/mL, and the LOQ was established at 0.186 µg/mL, indicating that even low concentrations of angiotensin could be detected and quantified effectively with the selected HPLC method.

1.3 Development of RTI dosage

1.3.1 Development of RTI dosage form for oxytocin

Large number of molecules (peptide and other sensitive chemical moieties) are unstable in aqueous and diluted form [13,14]. Various preliminary variables for development of RTI formulation for OXT were evaluated to acquire a final formulation with assay ranging 90-

110% and osmolarity range of 250-350 mOsmol/Kg. Therefore, different buffering agents (sodium acetate, tartaric acid, citric acid), amino acids (Glycine, L-methionine, L-arginine), metal ions ($MgCl_2$), osmogens (mannitol, sucrose, Trehalose, Lactose, dextrose, sodium chloride), stabilizer (HP β CD) and antioxidants (SMBS) were evaluated. The different compositions in PHC, AOB and TH82 bag were formulated and screened on the basis of their assay and osmolarity value. The assay was found to be below 90% in all trials taken in three different packaging materials. From initial trials, we concluded that PHC and AOB bag are better than TH82 bag. Hence, we selected PHC and AOB bag for further study for sequential screening of osmogens, buffers and stabilizers

Further, formulations were prepared with sodium acetate and citrate buffers with various stabilizers and filled in two different packaging materials. The formulations which were formulated with lactose, sucrose and sodium chloride (with HP β CD) have shown assay value within the limits. Based on the results obtained, sodium acetate as buffer, sodium chloride as osmogen, while HP β CD as stabilizer were found to be prominent compared to others. Further, the concentration of sodium acetate buffer and HP β CD were optimized. As sodium chloride is fixed at 0.9 mg/mL as optimum osmogen, sodium acetate and HP β CD were optimized from 0.01 and 0.5 mg/mL and 0.1 mg to 0.5 mg/mL respectively. On the basis of results, all the formulations prepared with different concentration of HP β CD and sodium acetate combination have shown assay values within the limits in both bags at initial stage. Subsequently, HP β CD was also evaluated to find its role in the stability of OXT. The effect can be clearly seen in the formulation with and without HP β CD, where it increased the stability of OXT after 3M at 25°C/40%RH. The assay of OXT was found to be 95% in formulation without HP β CD while nearly 97 % in formulation with HP β CD after 3M at 25°C/40%RH. The assay of formulation remained same when concentration of HP β CD increased from 0.1 to 0.5 mg/mL. Therefore, we decided to select lower concentration i.e. 0.1 mg/mL for further study.

Stability of any aqueous formulation depends on its pH. For a stable product, the pH of formulation should be constant over period of time [15]. With the optimized composition, five formulations of different pH (5.0, 4.5, 4.0, 3.5 and 3.0) were prepared. Formulations were tested at initial stage and for 3M at 25°C/40%RH. After 3M, results were compared with their respective initial results. pH variation of formulation over the period may change the physical and chemical properties of OXT RTI formulation. Initially, there were no remarkable

difference in assay values of all formulations, formulated at different pH. However, over the period of 3M at 25°C/40%RH, the assay value was decreased remarkably at pH 3.0 and 5.0. The formulation prepared at pH 4.0 had shown better stability after 3M among all tested formulations. Therefore, pH 4 was finalised for OXT RTI formulation. Further, autoclave study showed that OXT is thermolabile and cannot be autoclaved due to drastically decreased assay values compared to unautoclaved samples. Therefore, we decided for aseptic manufacturing process.

Freeze thaw study is important to find out the excursion storage condition during transport [16]. RTI formulation of OXT were placed on stability storage at -20°C for 24 h. Samples were then transferred to 40°C / 75%RH for 24 h. Procedure was repeated for a total of 14 cycles. Samples were analysed for Critical quality attributes (CQAs), assay, pH and osmolality after 7 and 14 cycles respectively. There was no remarkable difference in the assay, pH value, and osmolality of the formulation after 7 and 14 days of study. This signifies the robustness and stability of developed formulation. Much consideration was taken in selecting the packaging, given the fact that the main resource used to protect medications from the harmful effects of oxygen is the packing material. In addition, there are steps that must be taken in the development and manufacturing phases to ensure that excess oxygen isn't simply bottled or packaged with the medication [17]. Further, three formulations were prepared in presence of different gases viz air, nitrogen and oxygen. The formulations were filled and packed in respective environment. All the formulations were tested at initial stage and were kept on stability at 25°C/40%RH for 3M. After 3M, samples were withdrawn and analysed. The developed formulation was found to be stable in presence of nitrogen. However, formulations, that were prepared in presence of air and oxygen had shown prominent degradation with most significant degradation observed in formulation that was prepared in presence of oxygen.

Photostability testing was also undertaken to provide information necessary for manufacturing, handling, packaging, and labelling [18]. The assay of OXT in RTI formulation was found reduced when it was exposed to light. There was no effect on pH and osmolality of formulation. Therefore, utmost care should be taken during manufacturing, handling and packaging of OXT RTI. Further, study was conducted to evaluate the suitability of material of construction (MOC) of manufacturing vessel (SS316L) for bulk solution manufacturing. The study is usually executed by preparing a bulk solution and subsequently stored in manufacturing vessels at

room temperature (~20-25°C) for predefined period of time [19]. The outcome of vessel compatibility study suggested that in all four conditions, the product was compatible with manufacturing vessel up to 24 h. After 24 h and till end of study, the assay of product was found in decreasing trend. The rate of degradation of OXT was seen higher in case of unfiltered and without nitrogen environment. From vessel compatibility study, we concluded that formulation can be held for 24 in SS container without loss of potency of OXT.

Filter membrane compatibility study was also evaluated for different available filter membranes for their physical and chemical compatibility with product. A study was conducted to evaluate the compatibility and adsorption of OXT by filter membrane used and selection [20]. A bulk solution was prepared and passed through filter membranes (Nylon, PES, PVDF) separately and kept at room temperature (~20-25°C). Samples were withdrawn at Initial (0 h), 24 h, 48 h, and evaluated for drug product description, pH, Assay and particulate matters. The outcome of filter compatibility study suggested that the product is most compatible with PES membrane up to 48 h. After 24 h and till end of study, assay of the product was found in decreasing trend with Nylon and PVDF filter.

The stability study of OXT RTI formulation (0.02 IU/mL) was done at 5 ± 3 °C, 25°C/40%RH & 30°C/65%RH-6M. Obtained stability data was also processed with Minitab in order to evaluate in respect of time. RTI formulations were stored at 5 ± 3 °C, 25°C/40%RH and 30°C/65%RH for stability studies, and tested for assay, pH, osmolality, PMT, % absorbance, % Transmittance, and sterility. The % of assay changed from 102.2 ± 1.76 to 95.73 ± 0.95 after 24 M at 5 ± 3 °C, while 93.13 ± 1.01 after 12 M at 25°C/40%RH and 91.09 ± 1.06 after 6M at 30°C/65%RH-6M. OXT showed non-significant change at 5 ± 3 °C, while at 25°C/40%RH and 30°C/65%RH-6M, it showed changes in assay. Hence, the stability testing data indicated that RTI formulations of OXT stored at 5 ± 3 °C were more stable.

1.3.2 Development of RTI dosage form for vasopressin

In view of knowledge gathered during formulation development of OXT RTI and considering effect of concentration of different osmogens on osmolarity of formulation, various developmental trials were taken in order to stabilize Vasopressin in large volume aqueous based formulations. For this purpose, osmogens such as Sodium chloride, Mannitol, Lactose, Sucrose, Trehalose and Dextrose were evaluated [21]. In initial screening, pH was kept 3.7 as

per concentrate vasopressin data. All formulations were prepared with sodium acetate buffer (0.01mg/mL) with different osmogens and filled in two different packaging materials (PHC & AOB). The assay of formulations prepared with mannitol, dextrose sucrose, lactose, trehalose, and sodium chloride were found to be above 90% and within proposed specification (90-110%). But, assay in formulation containing sodium chloride as osmogen was found to be 100% in both bags (PHC & AOB), while others prepared by other osmogens were found to be below 98%. Further, to check the effect of HP β CD as stabilizer, same formulation with HP β CD was formulated in both bags and kept for 3M at 25°/40%RH. However, the effect of HP β CD was not significant compared to without HP β CD after 3M at 25°/40%RH. Based on the results, sodium chloride was selected as osmogen for further development.

For pH stability study, batches were formulated at pH 3.0, 3.3, 3.8, 4.3, 4.6 and 5.0, and kept for 3M at 25°C/40%RH. The decreasing assay for all pH formulations was observed after 3M, while other CQAs i.e. pH, osmolality, PMT, % of transmittance & absorbance were found unchanged. Over the period of 3M at 25°C/40%RH, the assay value was decreased remarkably at all pH except the formulation prepared at pH 3.8. Therefore, we decided to keep pH 3.8 in our formulation for further studies. In order to evaluate a suitable sterilization method, Vasopressin RTI formulation was sterilized at different recommended sterilization conditions, and analysed thereafter. In all sterilization conditions, assay of Vasopressin in RTI formulation was found remarkably reduced. However, no effect on pH and osmolarity of formulation was observed. Therefore, the process comprising sterile filtration, pre-sterilized container and aseptic processing was chosen for formulation.

To evaluate the photosensitivity of Vasopressin RTI, the samples (in infusion bag, in final pack and a control sample) were placed in the photostability chamber and exposed to light of 20 million lux for 24 hr. After exposure, the samples were withdrawn and analysed. The assay of Vasopressin in RTI formulation was found slightly reduced when it was exposed to light. There was no effect on pH and osmolarity of formulation. Therefore, utmost care should be taken while manufacturing, handling and packaging of Vasopressin formulation.

Vasopressin RTI was formulated after optimizing composition and process, and stability study was conducted as described in section of OXT RTI formulation. The stability study of vasopressin RTI formulation 1.887 μ g/mL (1 IU/mL) was done at 5 \pm 3 °C and

25°C/40%RH. A risk assessment was performed in order to identify the CQAs of drug product. Drug product quality attributes were assessed for likely impact on product safety and efficacy. The stability data was processed with statistical tool (Minitab) to find out appropriate statistical model and to extrapolate shelf-life of drug product while considering all major CQAs of formulation. The vasopressin assay was found non-significantly changed at $5 \pm 3^\circ\text{C}$, while found significantly decreased at 25°C/40%RH.

Percentage assay of vasopressin was found to decrease on storage at 25°C/40%RH, which may be due to instability of peptide molecules at higher temperature. This effect was least in case of formulation stored at $5 \pm 3^\circ\text{C}$, which indicates that degradation can be controlled by storing formulation at $5 \pm 3^\circ\text{C}$. There were no remarkable differences in initial value of pH and osmolarity when compared with end values observed after 12M. Hence, the stability testing data indicated that RTI formulations of Vasopressin stored at $5 \pm 3^\circ\text{C}$ were more stable.

Further, the extrapolation and stability report were generated as per ICH Q1E, and assay was found shelf life determining or indicating as there was statistically significant change happened during stability in both storage conditions, which is critical CQA to determine over all shelf life. Shelf life of another CQAs like Osmolality (mOsm/kg) and pH were found to be more compared to assay in both storage conditions. But, based on the stability data prediction as per ICH Q1E, overall shelf life was found to be 16.5 months and 25.36 months for 25°C/40%RH and $5\pm 3^\circ\text{C}$ respectively. The shelf life of OXT RTI is greater at $5 \pm 3^\circ\text{C}$. Thus, it can be concluded that even in the worst-case scenario, the stability of vasopressin RTI formulation in sodium chloride injection is expected to be more than 12M at 25°C/40%RH and 36M at $5\pm 3^\circ\text{C}$ for proposed specification. Peptides are available in small volume and stored at $5 \pm 3^\circ\text{C}$, but our developed formulation is large volume, so we recommend 25°C/40%RH storage condition for better feasibility and ease of transportation.

1.3.3 Development of RTI dosage form for angiotensin

In view of knowledge gathered during formulation development of OXT RTI, and Vasopressin RTI and considering effect of concentration of different osmogens on osmolarity of formulation, various developmental trials were taken in order to stabilize Angiotensin-II in large volume aqueous formulations. For this purpose, osmogens such as Sodium chloride, mannitol and Dextrose were evaluated. All formulations were prepared with various osmogens

and buffers, and filled in two different packaging materials (PHC & AOB). The assay of formulation prepared by mannitol in combination of sodium chloride was found to be 100% and within proposed specification (90-110%). However, for formulations prepared with other excipients, assay was not found to satisfactory at initial stage. Therefore, we decided to go with sodium chloride for further study.

For pH stability study, batches were formulated at pH 4.0, 4.5, 5.0, 5.5, 6.0 and 6.5, and kept for 3M at 25°C/40%RH. The decreasing assay for all pH formulations was observed after 3M, while other CQAs i.e. pH, osmolality, PMT, % of transmittance & absorbance were found stable. The assay difference after 3M for formulation with pH 5.5 was least compared to others. Therefore, we decided to keep pH 5.5 in our formulation for further studies.

In order to evaluate a suitable sterilization method, Angiotensin-II RTI formulation was sterilized at different recommended sterilization conditions and analysed. In all sterilization conditions recommended, the assay of Angiotensin-II in RTI formulation was found reduced. There was no effect on pH and osmolality of formulation. Therefore, the process comprising sterile filtration, pre-sterilized container and aseptic processing was found suitable for further use. To evaluate the photosensitivity of Angiotensin-II RTI, the samples (in infusion bag, in final pack and a control sample) were placed in the photostability chamber and exposed to light of 20 million lux. After exposure, the samples were withdrawn and analysed. The assay of Angiotensin-II in RTI formulation was found slightly reduced when it was exposed to light. There was no effect on pH and osmolality of formulation. Therefore, utmost care should be taken to manufacturing, handling and packaging of formulation of Angiotensin-II.

The stability study of angiotensin RTI formulation (0.01 mg/mL) was done at 5 ± 3 °C and 25°C/40%RH, as per ICH Q1E. A risk assessment was performed in order to identify CQAs of drug product. Drug product quality attributes were assessed for likely impact on product safety and efficacy. The stability data was processed with statistical tool (Minitab) to find out an appropriate statistical model and to extrapolate the shelf-life of drug product while considering all major CQAs of formulation. The optimal storage conditions for the formulation were evaluated by measuring the percentage of assay after specific intervals of 3, 6, 9, and 12 months. The percentage assay of Angiotensin-II was observed to decline when stored at 25°C/40%RH, possibly due to the instability of peptide molecules at elevated temperatures.

This degradation was less pronounced in the formulation stored at 5 ± 3 °C, suggesting that maintaining this temperature can help control degradation. No significant differences were observed in the initial pH and osmolarity values when compared to those recorded after 12 months. Therefore, the stability testing results showed that RTI Angiotensin-II formulations kept at 5 ± 3 °C were more stable. Nonetheless, it is also possible to store them at temperatures not exceeding 25°C/40%RH for up to 12 months without significant drug loss.

In light of the stability data predictions as prescribed by ICH Q1E, the overall shelf life was calculated to be approximately 16.41 months when stored at 25°C with 40% relative humidity, and an impressive 34.485 months when kept at a controlled temperature of 5 ± 3 °C. The extended shelf life at the lower temperature is attributed to the managed degradation of the assay, which helps maintain its integrity over time. Hence, it can be confidently concluded that even under the most challenging conditions, the stability of any angiotensin II RTI formulation is expected to last beyond 15 months at 25°C/40% RH and reach up to 36 months at the more favourable storage condition of 5 ± 3 °C, according to the proposed specifications.

All the tested RTI formulation samples have shown grade '0' in microscopic evaluation showing no *in vitro* reactivity. Similarly, in MTT test, all the tested samples have shown no *in vitro* reactivity. This indicates the biocompatibility of selected packaging materials.

1.4 Development of lipidic nanovesicles for nose to brain delivery

1.4.1 Formulation and characterization

Due to unfavourable drug conditions and the brain's selective barrier provides low absorption and therapeutic delivery [22]. The complex anatomical and physiology of blood-brain barrier (BBB) prevents active molecules to enter from brain or central nervous system (CNS) that makes brain delivery a herculean task [22]. Within the CNS and circulating blood vessels, interstitial fluid serves as main barrier [23]. These remains the largest obstacle in clinical development. Therefore, the study was designed to use OXT-loaded nanovesicles and Vaso-loaded nanovesicles for targeting the brain *via* intranasal route [24]. The optimized molar ratio of HSPC: MPEG (2000)-DSPE: Cholesterol for both nanovesicles was 4:1:1 The average particle size of OXT-nanovesicles (95.06 ± 0.86 nm) and Vaso-nanovesicles (99.06 ± 1.01) was smaller than 100 nm. Further, PDI of all nanovesicles was found to be < 0.2 , which suggests the homogeneity in their particle size distribution. The zeta potential of OXT-loaded

nanovesicles and Vaso-loaded nanovesicles formulation was estimated to be -22.1 ± 0.12 and -21.8 ± 0.17 mV respectively, which is probably due to the decoration of MPEG on the outer side of nanovesicles. The percentage drug entrapment (PDE) of OXT-loaded nanovesicles and Vaso-loaded nanovesicles was estimated to be 64.03 ± 0.54 and $62.59 \pm 0.39\%$ respectively.

ZP studies provide basis for stability of nanovesicles [25, 26]. The ZP of nanovesicles during stability was from -22.1 ± 0.12 to -23.4 ± 0.14 and -21.38 ± 0.24 at $5 \pm 3^\circ\text{C}$ and $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 6M and 3M respectively. The particle size increased from 99.06 ± 1.01 to 112.5 ± 4.54 , 124.1 ± 4.54 , at $5 \pm 3^\circ\text{C}$ and $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 6M and 3M respectively. The PS increase at $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ was significantly more compared to $5 \pm 3^\circ\text{C}$ after tested stability tenure. The PDI of nanovesicles almost remained same at both storage conditions throughout the stability. The % of drug assay was decreased from 99.32 ± 1.73 to 98.02 ± 1.12 at $5 \pm 3^\circ\text{C}$ after 6M, and to 97.21 ± 1.23 at $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 3M. OXT which was loaded in nanovesicles was more stable at $5 \pm 3^\circ\text{C}$ without loss of drug potency. Hence, we recommend $5 \pm 3^\circ\text{C}$ storage condition to get maximum shelf life.

The ZP of NVs during stability was from -21.8 ± 0.17 to -22.4 ± 0.84 and -24.8 ± 0.84 at $5 \pm 3^\circ\text{C}$ and $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 6M and 3M respectively. The particle size increased from 99.06 ± 1.01 to 112.5 ± 4.54 nm & 124.1 ± 4.54 nm at $5 \pm 3^\circ\text{C}$ and $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 6M and 3M respectively. The PS increase at $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ was significantly more compared to $5 \pm 3^\circ\text{C}$ after tested stability tenure. The PDI of NVs almost remained same at both storage conditions throughout the stability. The % of drug assay was decreased from 98.02 ± 1.87 to 96.89 ± 1.25 at $5 \pm 3^\circ\text{C}$ after 6M, while to 96.81 ± 1.78 at $25 \pm 2^\circ\text{C}/60 \pm 5\% \text{RH}$ after 3M. As vasopressin in NVs were more stable at $5 \pm 3^\circ\text{C}$ without loss of drug potency, we recommend $5 \pm 3^\circ\text{C}$ storage condition to get maximum shelf life.

1.4.2 Evaluation on monocytic cells (THP-1)

The study was intended to assess the effect of OXT, vasopressin, OXT-nanovesicles and Vaso-nanovesicles on the transcriptional pattern of apoptotic and inflammatory immune makers (caspase-3, 8, 9, Akt1, NF- κ B, Bcl, CD40, Bim, Bak, IL-6) [27, 28]. We saw the reduced expression of caspase-3 and 8 in the hTHP-1 cells treated with all formulations of vasopressin and OXT. Caspase-9 expression on the contrary was seen higher with the treated groups. A reduction in expression of inflammatory markers NfKB and IL-6 in the cells treated with all

formulations of vasopressin and OXT was observed. Vasopressin and OXT loaded nanovesicles treated cells saw a reduced expression of BCL-2, a regulator of cell death, as compared to the plain drug treatment. Interestingly, the co-stimulatory marker (CD40) that regulates the programmed death and pro-apoptotic gene Bak was seen reduced with all formulations treated hTHP-1 cells, whereas Bim expression was seen higher by the OXT formulation treated cells. Since cell death and inflammation are two interlinked phenomena, the relative mRNA expression of IL-6 was determined. OXT formulation treated hTHP-1 cells showed a highly significant reduction in the expression of pro-inflammatory marker, IL-6 as compared to the vasopressin and untreated control.

Further, the inactive transcription factor FOXO1 (phosphorylated FOXO1) and pro-apoptotic factor (Bim) work in tight regulation by the over-expression of co-stimulatory (CD40) mediating the signalling (PI3-Akt) pathway in hTHP-1 cells. Thus, using confocal microscopy, we examined the qualitative expression of FOXO1 in LPS-stimulated hTHP-1 cells. After one hour of LPS stimulation, our data revealed a minor variation in the qualitative expression of FOXO1 between LPS-stimulated and unstimulated cells. Additionally, for FOXO1, we estimated the fluorescence intensity of cells counted in different fields. Compared to the unstimulated control, our data demonstrated FOXO1 expression [29-32]. The drug encapsulated in the nanovesicles showed better results compared to plain drug while OXT-AEEA complex showed the best result amongst all tested formulation due to better cell permeability. Also, we calculated the immunoblotting intensity of cells counted in different fields for NfKB and BIM. Our results showed an amenable difference in the expression of FOXO1 and Bim than the un-stimulated control.

1.4.3 *Ex vivo* evaluation on SH-SY5Y

The *in vitro* cell viability studies on SH-SY5Y were done by MTT assay. OXT and vasopressin alone and encapsulated into nanovesicles showed good biocompatibility and 85-90% cells were viable after 72 hr. Further, SH-SY5Y cell uptake study of coumarin-6 (C-6) co-encapsulated nanovesicles (C-6, C-6+OXT and C-6+AEEA-Oxytocin) formulations was carried out to determine internalization efficiency of nanovesicles. Nanovesicles showed greater uptake in SH-SY5Y. The results obtained with cell uptake study demonstrated

remarkably higher internalization of OXT-nanovesicles and vasopressin-nanovesicles after 3h incubation.

The comprehensive study examining cell uptake of C6-OXT-nanovesicles, specifically the C6-Vaso-nanovesicles, was conducted using SH-SY5Y cells to evaluate the effectiveness with which these nanovesicles are internalized by the cells. The results from this meticulous cell uptake evaluation revealed a strikingly higher internal localization of both OXT-nanovesicles and vasopressin-nanovesicles following an incubation period of 3 h. These findings serve to support the hypothesis regarding the cellular uptake of nanovesicles, as indicated by the persistent and vibrant fluorescence signals detected after 3 h of incubation with the C-6 co-encapsulated nanovesicles. The effect of the OXT, vasopressin, OXT-loaded nanovesicles and vasopressin-loaded nanovesicles on the SH-SY5Y cells was evaluated by observing cellular morphology at higher concentration (100µg/mL). After the treatment with pure drugs and drug loaded nanovesicles for 48 h, the alterations in the morphology of cells were not detected under a phase contrast microscope. In SH-SY5Y cells treated with formulation, we could not see any changes in characteristic features of apoptosis, such as disruption of a cell wall, shrinkage of the cell, and decrease in the number of living cells, compared to control group.

Apoptosis was qualitatively characterized in SH-SY5Y cells after treatment with pure OXT and vasopressin, OXT loaded nanovesicles and vasopressin loaded nanovesicles by DAPI and dual (AO/EB) staining technique. Normal SH-SY5Y cells showed intact nuclei and exhibit modest DAPI fluorescence in SH-SY5Y cells treated with OXT, vasopressin, OXT loaded nanovesicles and vasopressin loaded nanovesicles. No morphological alterations of nuclei associated with apoptosis were seen, including nuclear condensation, enhanced brightness, and nuclear crinkle, as further corroborated by AO/EB staining. Cells in the control group remained viable and exhibited green fluorescence in a circular arrangement, with the nucleus evenly distributed at the centre.

1.4.4 Evaluation in AD induced animal model

1.4.4.1 Oxytocin loaded nanovesicles

Nanovesicles containing drugs were administered through intranasal (IN) and intravenous (IV) methods, and their effects were compared to those of a free drug solution also given via these routes, using the MWM test [33–37]. The Morris water maze test clearly depicted about

breakthrough enhancement in efficacy of nanovesicle OXT when delivered via intranasal route. The average mean time incurred for mice to reach on hidden platform was 37.16 ± 6.75 seconds. Similarly, average time incurred for SCP mice to reach on hidden platform was 58.66 ± 1.18 seconds. Mice administered with OXT via intranasal route were able to reach hidden platform in 45.58 ± 4.45 seconds i.e., 1.23 and 0.78 times of placebo and SCP treated group. Similarly, mice administered with OXT via i.v. route was able to reach hidden platform in 42.73 ± 8.30 seconds i.e., 1.15 and 0.73 times of placebo and SCP treated group. However, mice administered with nanovesicle loaded OXT via intranasal route were able to reach hidden platform in 28.36 ± 8.56 seconds i.e., 0.76 and 0.48 times of placebo and SCP treated group. Similarly, mice administered with nanovesicle loaded OXT via intravenous route were able to reach hidden platform in 51.45 ± 6.25 seconds i.e., 1.38 and 0.88 times of placebo and SCP treated group. To confirm molecular effectiveness of treatment. Gene expression studies of brain homogenate samples were studied for AIF-1, BDNF, GFAP, S100B analysis.

Gene expression studies were focused on analysing brain homogenate samples, which provided deep insights into the expression levels of key biomarkers. Specifically, the investigation examined the following factors: AIF-1 (Allograft inflammatory factor 1), known for its role in inflammation; BDNF (brain-derived neurotrophic factor), a critical protein involved in the survival and growth of neurons; GFAP (glial fibrillary acidic protein), a marker of astrocytic activation; IL-6 (interleukin-6), an important cytokine involved in inflammatory responses; and Nrf 2 (nuclear related factor 2), a vital regulator of antioxidant response. These analyses are instrumental in understanding the underlying molecular mechanisms and potential therapeutic effects of the treatment [38-40]. BDNF expression was found to be highly expressive in case of nanovesicle OXT when administered via intranasal route. The expression of BDNF follows pattern as: Nanovesicle OXT via intranasal route > OXT via intranasal route > OXT via intravenous route > Nanovesicle OXT via intravenous route. BDNF expression explains antioxidant and cholinergic transmission. Thus, BDNF gene expression studies demark the efficacy studies of best treatment groups i.e., nanovesicle OXT delivered via intranasal route. This might be due to protective sheath for OXT in lipid layer and protection of it from physiological attacks of nasal environment. However, similar situation does not prevail with OXT loaded in nanovesicles when administered via intravenous route. This might be due to incapability of lipidic vesicles that release OXT in systemic circulation and

minimized brain delivery of it. Thus, OXT provided prominent antioxidant effect in all treatment groups associated with it. AIF-1 is a prominent neurodegeneration marker linked to calcium binding adaptor molecule-1 with its genesis from macrophages, microglial cells, and neutrophils. Thus, AIF-1 gene expression studies demark the efficacy studies. Ideally, these studies are expressed in reverse mode as expressed in BDNF expression studies. For further confirmation, S100B gene expression studies were done. S100B is a member of the S100 protein family. It is a cytosolic calcium-binding protein concentrated in astrocytes, and therefore is released following astroglial injury. It is highly expressed in neuroglial cells, and thus is used as a marker of neuronal damage/neurodegeneration. Thus, these expression studies clearly depict about prominent neutralization effect of OXT when delivered via intranasal route loaded in nanovesicles. The expression of GFAP was studied due to its linkage with amyloid theory and its neuroinflammation. It was done as confirmatory test to verify SCP model.

The biochemical evaluation of brain homogenate samples of treated animals was done for free OXT solution (i.v. and i.n), OXT loaded lipidic carriers (i.v. & i.n.) in comparison with positive (naïve) and negative control group (SCP-treated). The only SCP treated animal group showed elevated levels of MDA (lipid peroxidation indicator) and reduced GSH content (antioxidant). Stress levels like nitrite and H₂O₂ also increased with the increase in MDA levels in the presence of SCP. While OXT and OXT loaded nanovesicles were found to manage the normal biochemical level when treated with SCP. The biochemical levels in the SCP treated mice group were found to be noteworthy in the naïve group. In GSH studies, the antioxidant level tends to be the highest in the treatment group in comparison to control group. The SCP tends to decrease the amount of GSH (an antioxidant) and increase MDA (a measure of lipid peroxidation). When MDA levels rise in the presence of SCP, stress levels such as nitrite and H₂O₂ also rise. Therefore, a considerable decrease in the levels of MDA, nitrite, and H₂O₂ was noted for formulation based on the biochemical estimation. The naïve group's levels of each of these parameters were found to be significantly higher than those of the SCP-treated group. In GSH investigations, the treatment group typically had the highest antioxidant level when compared to control group

Further, the comparative difference in the effectiveness of the formulation suggested in the current study is indicated by the histological evaluation of hippocampal observations. The higher the neurons density, more effective was treatment. The density of neurons was found to

be higher in naïve group followed by OXT loaded nanovesicle formulation delivered via intranasal route, OXT delivered via intranasal route, OXT delivered via intravenous route, OXT loaded nanovesicle formulation delivered via intravenous route and SCP treated group.

1.4.4.2 Vasopressin loaded nanovesicles

The Morris water maze test for vasopressin loaded nanovesicles clearly depicted about breakthrough enhancement in efficacy of nanovesicle vasopressin when delivered via intranasal route. Nanovesicle vasopressin when delivered via intranasal route exhibited 1.31 times efficacy when same formulation was administered via intravenous route. Similar results were observed for Vasopressin when delivered *via* intranasal route exhibited 1.30 times efficacy when same formulation administered *via* intravenous route. The lowest efficacy of vasopressin administered via intravenous route might be owing to possible degradation of vasopressin in nasal medium. The promising effect in case of nanovesicle vasopressin when administered via intranasal route might be due to proper encapsulation of vasopressin in lipidic vesicles that prevent the physiological attack of nasal environment.

To confirm molecular effectiveness of above treatment, gene expression studies were prominent. Gene expression studies of vasopressin and vasopressin loaded nanovesicles treated animal brain homogenate samples were studied for Allograft inflammatory factor 1 (AIF-1), S100B, brain-derived neurotrophic factor (BDNF), and glial fibrillary acidic protein (GFAP) analysis. BDNF expression explains antioxidant and cholinergic transmission. Thus, BDNF gene expression studies demark the efficacy studies of best treatment groups i.e., vasopressin delivered via intranasal route. This might be due to hydrophilicity of vasopressin in olfactory route. However, similar situation does not prevail with Vasopressin loaded in liposome when administered via intranasal. This might be due to incapability of lipidic vesicles that release vasopressin in nasal physiology. Thus, vasopressin provides prominent antioxidant effect in all treatment groups associated with it.

AIF-1 was a prominent neurodegeneration marker linked to calcium binding adaptor molecule-1 with its genesis from macrophages, microglial cells, and neutrophils. Thus, AIF-1 gene expression studies demark the efficacy studies. Ideally, these studies to be expressed in reverse mode as expressed in BDNF expression studies and same case was observed. For further confirmation, S100B gene expression studies were done. S100B is a member of the S100

protein family. It is a cytosolic calcium-binding protein concentrated in astrocytes, and therefore is released following astroglial injury. It is highly expressed in neuroglial cells, and thus is used as a marker of neuronal damage/neurodegeneration. Thus, these expression studies clearly depict about prominent neutralization effect of Vasopressin when delivered via intranasal route loaded in nanovesicles.

1.5 AEEA-Oxytocin Conjugates for nose to brain delivery

In contemporary practice, the modification of peptides employs sophisticated techniques from medicinal chemistry, designed to not only replicate but also stabilize. The primary objectives of these modifications are to enhance biological activity of with improved selectivity, stability, and solubility [41-46].

The advancement of stabilized peptides can be realized through a diverse array of methodologies. These methods are not limited to comprehensive chemical synthesis, intricate peptide modification processes, and development of peptidomimetics. Additionally, techniques such as cyclization, modifications at backbone and side chains of peptides, and replication of structural elements like α -helices and β -sheets are crucial. Further innovations arise from recombinant technology, which enables expansion of genetic code. Another technique, PEGylation enhances solubility and half-life of therapeutic peptides. Furthermore, the development of covalent peptide drugs represents another pivotal area within this vibrant field, showcasing the continuous evolution of peptide design to meet therapeutic needs [47].

1.5.1 Synthesis and Characterization of AEEA-Oxytocin

The AEEA-OXT was synthesised by solid phase sequential amino acid method which involved Manufacturing of AEEA-OXT-Stage-H-(01-10)-Resin followed by synthesis of AEEA-OXT. Following an initial transformation, the crude product was solubilized and subjected to a cyclization reaction using iodine solution and subsequent purification to isolate final compound. The final step involved desalting of solution which achieved by introducing a 50% acetonitrile solution, containing 1% acetic acid in water, effectively removing any remaining salts and impurities. Ultimately, the purified solution was lyophilized, resulting in a dry form of AEEA-OXT [48].

The conjugation of AEEA with OXT was investigated using FT-IR spectroscopy in order to determine the C-C bond formation confirmation in AEEA-OXT. Spectral output was recorded by the transmittance as a function of wave number. Additional -C-O- stretching band (1050-1150 cm^{-1}) was observed compared to plain OXT IR spectra which confirmed the conjugation between OXT and AEEA in AEEA-OXT molecule.

Further conjugation of AEEA-OXT was confirmed by NMR. Twelve number of proton signal was found to be between 0.98-0.99 that represents the proton present in primary aliphatic carbon which confirms the isoleucine/leucine amino acid. Similarly, chemical shift from 1.19 to 1.61 and 1.62-3.77 represents number of protons present in aliphatic tertiary and secondary carbon respectively. Hence, 2 protons in tertiary and 22 protons in secondary carbon confirmed isoleucine/leucine and CH_2 for all amino acid respectively. Chemical shift from 3.81 to 4.88 represented the 8 protons present in chiral carbon, and 6.85 to 7.21 represented the 4 protons present in chiral carbon of tyrosine. Overall, the presence of protons confirmed the structure of amino acids of OXT. 2-(2-(2-Aminoethoxy) ethoxy) acetic acid was successfully conjugated with OXT which was confirmed by NMR spectroscopy.

2-(2-(2-Aminoethoxy) ethoxy) acetic acid was successfully conjugated with OXT and further confirmed by Mass spectroscopy. The total mass of AEEA-OXT was calculated 1151.509 that confirmed the conjugation of OXT with AEEA.

1.5.2 Evaluation on SH-SY5Y neuro cells

The cell viability study was conducted in SH-SY5Y cells employing MTT assay to investigate the biocompatibility of OXT and AEEA-OXT towards tested cells [49]. OXT and AEEA-OXT, in 1 $\mu\text{g/mL}$, 10 $\mu\text{g/ml}$ and 100 $\mu\text{g/ml}$ concentration, incubated with SH-SY5Y neuro cells for 24, 48 and 72h was calculated. We found above 85% cell viability during increasing concentration at given time points (24hr, 48hr and 72hr) with OXT and AEEA-OXT. The conjugation of peptide with AEEA exhibited similar neuro protective potential compared to that seen with plain OXT. In conclusion, we did not find significant reduction of cell viability during increasing concentration at incubated time points with OXT and AEEA-OXT. The outcome of current study suggests that OXT retained its compatibility on neuro cells even after being conjugated with AEEA and not have any impact on its neuro protective potential.

The quantitative cell uptake study of OXT and AEEA-OXT was carried out in SH-SY5Y cells to determine the internal localization proficiency. The data obtained of cell uptake evaluation study confirmed remarkably higher internal localization of OXT and AEEA-OXT after 3 h incubation. Maximum cell uptake was estimated to be 0.4 mg/mL that confirms the concentration dependent cellular uptake. Time-dependent cellular internalization of OXT and AEEA-OXT was demonstrated in the cell uptake investigation, and increasing the incubation period from 1 to 2 h significantly enhanced the amount of OXT that was taken up by the cells. Significant changes in cell uptake over time were observed when the incubation period was extended from 2 h to 3 h. In conclusion, time and concentration dependable cellular uptake was found for OXT and AEEA-OXT.

The effect of the OXT and AEEA-OXT on the SH-SY5Y cells was further evaluated by observing cellular morphology. After the treatment with pure OXT and its conjugation with AEEA (AEEA-OXT) for 48 h, the morphology of cells remained same as control and not detected any change compared to control under a phase contrast microscope. The comprehensive study examining qualitative uptake of C-6, C6+OXT and C-6+AEEA-OXT, was conducted using SH-SY5Y cells to evaluate the effectiveness of conjugation in internalization by the cells. The results from this meticulous cell uptake evaluation revealed a slightly higher internal localization of AEEA-OXT following an incubation period of three h. The findings serve to support the hypothesis regarding the cellular uptake of AEEA-OXT, as indicated by the persistent and vibrant fluorescence signals detected after three h of incubation with the C-6 + AEEA- OXT.

There was almost same emission of fluorescence of 100 μ L/mL of OXT and AEEA-OXT in the reaction of generated ROS compared to control cells, which was indirectly correlated to biocompatibility and no effect on apoptosis cascade activation of the cells treated with pure drug formulations. The ROS analysis outcome suggested that OXT retained its biocompatibility on neuro cells even after being conjugated with OXT. AEEA- OXT also showed the similar neuro protective potential as seen with plain OXT. Apoptosis was qualitatively characterized in SH-SY5Y cells after treatment with OXT and AEEA-OXT by DAPI and dual (AO/EB) staining technique. Normal SH-SY5Y cells have intact cell nuclei and were stained with faint fluorescence of DAPI. Cells in the control group were also alive

and emitted green fluorescence in a circular pattern, and the nucleus was uniformly dispersed across the centre.

1.5.3 Evaluation of AEEA- OXT on monocytic cells (THP-1)

Genomic microarray (qRT-PCR) analysis in Human THP-1 cells were done as mentioned in previous chapter section 5.3.6.2.1. The mRNA expression was quantified by the changes in threshold method ($\Delta\Delta CT$) and normalized to the house keeping ACTB mRNA (encoding β actin) expression [50-52]. The study was intended to assess the effect of OXT and AEEA-OXT on the transcriptional pattern of inflammatory immune and apoptotic makers (NF- κ B, IL-6 Akt1, BCL, CD40, Bim, Bak, caspase-3, 8, 9). We observed a decrease in the levels of caspase-3 and caspase-8 in the hTHP-1 cells that were treated with OXT and AEEA-OXT. Caspase-9 expression on the contrary was seen higher with the treated group. The expression levels of the pro-apoptotic markers did not achieve statistical significance. It was noted that there was a decrease in the expression of the inflammatory markers NfKB and IL-6 in cells treated with all OXT and AEEA-OXT. Remarkably, the co-stimulatory markers (CD40) that regulates the programmed cell death and pro-apoptotic gene Bak was seen reduced with all formulations incubated with hTHP-1 cells, whereas Bim expression was seen higher in the cells which were treated with OXT formulations. OXT and AEEA-OXT treated hTHP-1 cells showed remarkable reduction in the expression of pro-inflammatory marker IL-6, as compared to the control.

The inactive transcription factor FOXO1 (phosphorylated FOXO1) work in tight regulation by the over-expression of co-stimulatory (CD40) mediating the signalling (PI3-Akt) pathway in hTHP-1 cells. Thus, using confocal microscopy, we examined the qualitative expression of FOXO1 in LPS-stimulated hTHP-1 cells. Following one hour of LPS stimulation, our results showed a significant difference in the qualitative expression of FOXO1 when comparing LPS-stimulated cells to those that were unstimulated. Additionally, for FOXO1, we estimated the fluorescence intensity of cells counted in different fields. Compared to the unstimulated control, our data demonstrated evident FOXO1 expression. The OXT and AEEA-OXT showed better results compared to LPS stimulated cells.

1.5.4 Neurological effects in experimental animals

While *In vitro* assessments of drug release and targeting are crucial, neurological disorders are multifactorial, complex diseases involving many physiological processes [53-57]. Morris water maze (MWM) test was evaluated to compare the free OXT and AEEA-OXT administered via i.n. route against positive control (Naïve) and negative control group (SCP only). The mean time incurred for mice to reach on hidden platform was 37.16 ± 6.75 seconds. Similarly, average time incurred for SCP mice to reach on hidden platform was 58.66 ± 1.18 seconds. Mice administered with OXT via intranasal route were able to reach hidden platform in 39.58 ± 4.45 seconds i.e., 1.07 and 0.67 times of placebo and SCP treated group. Mice administered with OXT conjugate administered *via* the intranasal route were able to reach hidden platform in 26.45 ± 4.23 seconds i.e., 0.72 and 0.45 times of placebo and SCP treated group. This study clearly depicted about breakthrough enhancement in efficacy of OXT conjugate administered via the intranasal route. The memory of mice treated with AEEA-OXT *via* i.n was not only regained but also improved, and mice were found able to reach the hidden platform compared to placebo group.

Gene expression studies of OXT and AEEA-OXT treated animal brain homogenate samples were studied for AIF-1, S100B, BDNF, and GFAP analysis. BDNF, GFAP and S100b was found to be highly expressive in OXT and AEEA-OXT administered via i.n. treated group. The expression level of these was found to be in following order: Control > SCP+AEEA-OXT > SCP+OXT > SCP. AIF expression studies were observed to be as per BDNF expression. The expression level of AIF was found to be in following order: Control < SCP+AEEA-OXT < SCP+OXT < SCP. Almost equivalency in expression of AIF gene was observed in OXT conjugate < OXT via intranasal route.

The brain homogenate biochemical studies were done for naïve, SCP-treated, free OXT solution (i.n) and AEEA-OXT (i.n). In GSH investigations, treated group showed the highest antioxidant level when compared to other treated group. The SCP tends to decrease GSH content (antioxidant) and increase MDA levels (lipid peroxidation biomarker). When SCP is present, stress levels such as nitrite and H_2O_2 also rise in tandem with an increase in MDA levels. As a result, the biochemical estimation indicated that the formulation's MDA, nitrite,

and H₂O₂ levels were notably decreased. It was found that the naïve group's levels of each of these parameters were significantly higher than those of the SCP-treated animal group.

The histological assessment of hippocampal observations indicates the relative differences in the effectiveness of the formulation suggested in the present study. The density of neurons was found to be higher in naïve group followed by AEEA-OXT delivered via i.n. route, OXT delivered via i.n. route, SCP treated group indicating the neuroprotective efficacy of AEEA-OXT.

2. CONCLUSIONS

The present research endeavour was initiated to thoroughly investigate and resolve the existing gaps and shortcomings in injectable dosage forms, especially in case of peptide therapeutics, with a particular focus on enhancing therapeutic outcomes through the utilization of a carrier approach. This initiative aimed to effectively reach and target the specific site of action required for optimal therapeutic intervention. To achieve this goal, the studies were diligently planned and executed in a systematic manner, ensuring that all crucial aspects and dimensions of the research were comprehensively covered. Below, the key outcomes derived from this extensive planning are articulated in detail.

The field of analytics was recognized as a fundamental requirement for measuring and determining the quantitative levels of drugs in a variety of investigative studies. Therefore, robust analytical methods were developed for OXT, vasopressin, and angiotensin. Furthermore, an analysis of the challenges encountered during the dilution process, along with the related stability concerns associated with ready-to-infuse dosage forms, has led to the successful design, development, and optimization of tailored RTI (ready-to-infuse) delivery systems for OXT, vasopressin, and angiotensin-II. These innovative systems were developed specifically to tackle the unique challenges posed by the selected peptides. The RTI formulation technique developed represents a ground breaking combination of composition and process, aimed at producing injections of sensitive molecules that contain low concentrations of active ingredients. This advancement not only enhances patient adherence to treatment protocols but also significantly improves safety outcomes. The paramount importance of safety in RTI systems is underscored by their distinctive characteristics that minimize administration errors and reduce the risk of cross-contamination.

In the next segment, the focus shifts to the promising area of nose-to-brain delivery for OXT and vasopressin. Innovative formulation strategies employed during this phase of the research utilized novel components, including phospholipids and strategically designed carriers, to significantly enhance the permeation of these drugs into the brain. This methodology is particularly noteworthy as it incorporates lipid-based nanovesicles specifically targeting conditions such as Alzheimer's disease. A thorough review of the background literature reveals that while a considerable volume of work has already been accomplished in this research area, there remains a pressing need for further advancement to fulfil the unmet expectations related to the two specified drugs, OXT and vasopressin. Consequently, after setting varied and diverse objectives across different research dimensions, the studies were executed in a systematic fashion.

In addition, the extended research incorporated focused efforts to address the identified deficiencies in OXT delivery through the application of a conjugation strategy aimed explicitly at nose-to-brain delivery. This innovative conjugation approach was designed to enhance the efficiency of the drug's permeation into the brain, thereby improving its therapeutic potential.

3. FUTURE PERSPECTIVES

We can assert with confidence that the developed RTI formulation, alongside the innovative nanovesicle and synthesized AEEA-OXT-based delivery systems, hold the promise of transforming the behaviour of these molecules by manipulating their diverse physicochemical and biological properties through strategic design methods. Such advancements are poised to enhance the transport characteristics of the drugs, which will ultimately translate into improved efficacy across various investigational models, with safety being concurrently emphasized. However, there is a clear demand for further in-depth studies, particularly focusing on two significant aspects: the industrial considerations regarding process scale-up and the establishment of standardization parameters paired with clinically oriented research. Collectively, the findings of this work, augmented by such studies, have the potential to provide substantive value to the therapeutic arsenal available to practicing clinicians.

4. REFERENCES

- 1 Panchal K, Katke S, Dash SK, Gaur A, Shinde A, Saha N, Mehra NK, Chaurasiya A. An expanding horizon of complex injectable products: development and regulatory considerations. *Drug delivery and translational research*. 2023 Feb;13(2):433-72.
- 2 Jain A, Kesharwani P, Garg NK, Jain A, Jain SA, Jain AK, Nirbhavane P, Ghanghoria R, Tyagi RK, Katare OP. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. *Colloids and Surfaces B: Biointerfaces*. 2015 Oct 1;134:47-58.
- 3 Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. *Journal of Controlled Release*. 2010 Dec 20;148(3):359-67.
- 4 Kumar S, Garg NK, Jain A, Khopade A, Pandey P, Sawant KK. Nanocarriers mediated delivery of methotrexate is instrumental in treating auto-immune diseases and cancer. *Journal of Drug Delivery Science and Technology*. 2023 Oct 1;88:104969.
- 5 Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. *Nature reviews Drug discovery*. 2014 Sep;13(9):655-72.
- 6 Gupta V, Jain AD, Gill NS, Guptan K. Development and validation of HPLC method-a review. *International research journal of pharmaceutical and applied sciences*. 2012 Aug 31;2(4):17-25.
- 7 Kazakevich YV, Lobrutto R. *HPLC for pharmaceutical scientists*. John Wiley & Sons; 2006 Dec 13.
- 8 Ahuja S, Rasmussen H. *Development for Pharmaceuticals, Vol. 8 Separation Science and Technology*.
- 9 Azim M.S., Mitra M., Bhasin P.S. HPLC method development and validation: A review. *Int. Res. J. Pharm.* 2013 4(4): 39-46.
- 10 Prathap B, Rao GH, Devdass G, Dey A, Harikrishnan N. Review on stability indicating HPLC method development. *International Journal of Innovative Pharmaceutical Research*. 2012;3(3):229-37.

- 11 Garg NK, Sharma G, Singh B, Nirbhavane P, Katare OP. Quality by design (QbD)-based development and optimization of a simple, robust RP-HPLC method for the estimation of methotrexate. *Journal of Liquid Chromatography & Related Technologies*. 2015 Oct 21;38(17):1629-37.
- 12 Charde MS, Welankiwar AS, Kumar J. Method development by liquid chromatography with validation. *International Journal of Pharmaceutical Chemistry*. 2014;4(02):57-61.
- 13 Shi M, McHugh KJ. Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. *Advanced Drug Delivery Reviews*. 2023 Aug 1;199:114904.
- 14 Brayden DJ, Hill TA, Fairlie DP, Maher S, Mrsny RJ. Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches. *Advanced drug delivery reviews*. 2020 Jan 1;157:2-36.
- 15 Vázquez-Blanco S, González-Freire L, Dávila-Pousa MC, Crespo-Diz C. pH determination as a quality standard for the elaboration of oral liquid compounding formula. *Farmacia Hospitalaria*. 2018 Nov 1;42(6):221-7.
- 16 Arana C, Ji J, Krug E, Liu J, McCaig L, Rozaieski B, Santos C, Sloan J, Charles AM, Wiegeshoff F. Industry Perspective on Temperature Cycling Studies to Meet Regulatory Temperature Excursion Support Requirements: Survey Outcome and Recommendations. *Journal of Pharmaceutical Sciences*. 2023 Sep 27.
- 17 Gabrič A, Hodnik Ž, Pajk S. Oxidation of drugs during drug product development: problems and solutions. *Pharmaceutics*. 2022 Jan 29;14(2):325.
- 18 Allain L, Baertschi SW, Clapham D, Foti C, Lantaff WM, Reed RA, Templeton AC, Tønnesen HH. Implications of in-use photostability: Proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 3. Oral drug products. *Journal of pharmaceutical sciences*. 2016 May 1;105(5):1586-94.
- 19 Investigation of the Properties of 316L Stainless Steel after AM and Heat Treatment
- 20 Othman NH, Alias NH, Fuzil NS, Marpani F, Shahrudin MZ, Chew CM, David Ng KM, Lau WJ, Ismail AF. A review on the use of membrane technology systems in developing countries. *Membranes*. 2021 Dec 27;12(1):30.

- 21 Garrett ER. Prediction of stability of drugs and pharmaceutical preparations. *Journal of Pharmaceutical Sciences*. 1962 Sep 1;51(9):811-33.
- 22 Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. *BioMed research international*. 2014;2014(1):869269.
- 23 Handa M, Singh A, Bisht D, Kesharwani P, Shukla R. Potential of particle size less than 15 nm via olfactory region for direct brain delivery via intranasal route. *Health Sciences Review*. 2022 Sep 1;4:100038.
- 24 Clayton KN, Salameh JW, Wereley ST, Kinzer-Ursem TL. Physical characterization of nanoparticle size and surface modification using particle scattering diffusometry. *Biomicrofluidics*. 2016 Sep 1;10(5).
- 25 Rodriguez-Loya J, Lerma M, Gardea-Torresdey JL. Dynamic light scattering and its application to control nanoparticle aggregation in colloidal systems: a review. *Micromachines*. 2023 Dec 22;15(1):24.
- 26 Pardridge WM. Drug transport across the blood–brain barrier. *Journal of cerebral blood flow & metabolism*. 2012 Nov;32(11):1959-72.
- 27 Lopez-Suarez L, Al Awabdh S, Coumoul X, Chauvet C. The SH-SY5Y human neuroblastoma cell line, a relevant in vitro cell model for investigating neurotoxicology in human: Focus on organic pollutants. *Neurotoxicology*. 2022 Sep 1;92:131-55.
- 28 Garg NK, Singh B, Sharma G, Kushwah V, Tyagi RK, Jain S, Katare OP*. Development and characterization of single step self-assembled lipid polymer hybrid nanoparticles for effective delivery of Methotrexate. *RSC Advances* 2015;5 (77): 62989-62999.
- 29 Dravid A, Raos B, Svirskis D, O’Carroll SJ. Optimised techniques for high-throughput screening of differentiated SH-SY5Y cells and application for neurite outgrowth assays. *Scientific reports*. 2021 Dec 14;11(1):23935.
- 30 Garg NK, Singh B, Kushwah V, Sharma R, Tyagi RK, Jain S, Katare OP*. The ligand (s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics. *Nanomedicine: Nanotechnology, Biology, and Medicine* 2016; 12: 2043–2060.
- 31 Dong QM, Ling C, Zhao L. Immunofluorescence analysis of cytokeratin 8/18 staining is a sensitive assay for the detection of cell apoptosis. *Oncology letters*. 2015 Mar 1;9(3):1227-30.

- 32 Barth M, Toto Nienguesso A, Navarrete Santos A, Schmidt C. Quantitative proteomics and in-cell cross-linking reveal cellular reorganisation during early neuronal differentiation of SH-SY5Y cells. *Communications Biology*. 2022 Jun 7;5(1):551.
- 33 Maher R, Moreno-Borralló A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. *Pharmaceutics*. 2023 Mar;15(3):746.
- 34 Handa M, Sanap SN, Bhatta RB, Patil GP, Ghose S, Singh DP, Shukla R, Rahul Shukla. Combining donepezil and memantine via mannosylated PLGA nanoparticles for intranasal delivery: Characterization and preclinical studies, *Biomaterials Advances*, 2023, 154, 213663
- 35 Handa M, Sanap SN, Bhatta RB, Patil GP, Ghose S, Singh DP, Shukla R, Rahul Shukla. Simultaneous Intranasal Codelivery of Donepezil and Memantine in a Nanocolloidal Carrier: Optimization, Pharmacokinetics, and Pharmacodynamics Studies. *Molecular Pharmaceutics* Vol 20/Issue 9
- 36 Livak KJ, Schmittgen TD, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method. *Methods* Volume 25, Issue 4, December 2001, Pages 402-408
- 37 Maher R, Moreno-Borralló A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. *Pharmaceutics*. 2023 Mar;15(3):746.
- 38 Dighe S, Jog S, Momin M, Sawarkar S, Omri A. Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer's Disease Management. *Pharmaceutics*. 2023 Dec 29;16(1):58.
- 39 Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. *Nature protocols*. 2006 Aug;1(2):848-58.
- 40 Yang ZF, Ho DW, Lau CK, Lam CT, Lum CT, Poon RT, Fan ST. Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. *International immunology*. 2005 Nov 1;17(11):1391-7.
- 41 Kaneko Y, Pappas C, Tajiri N, Borlongan CV. Oxytocin modulates GABAAR subunits to confer neuroprotection in stroke in vitro. *Scientific reports*. 2016 Oct 21;6(1):35659.

- 42 Morales T. Recent findings on neuroprotection against excitotoxicity in the hippocampus of female rats. *Journal of neuroendocrinology*. 2011 Nov;23(11):994-1001.
- 43 Chilumuri A, Milton NG. The Role of Neurotransmitters in Protection against Amyloid- β Toxicity by KiSS-1 Overexpression in SH-SY5Y Neurons. *International Scholarly Research Notices*. 2013;2013(1):253210.
- 44 Handa M, Singh A, Bisht D, Kesharwani P, Shukla R. Potential of particle size less than 15 nm via olfactory region for direct brain delivery via intranasal route. *Health Sciences Review*. 2022 Sep 1;4:100038.
- 45 Pardridge WM. Drug transport across the blood–brain barrier. *Journal of cerebral blood flow & metabolism*. 2012 Nov;32(11):1959-72.
- 46 Trevino JT, Quispe RC, Khan F, Novak V. Non-invasive strategies for nose-to-brain drug delivery. *Journal of clinical trials*. 2020;10(7).
- 47 Di L. Strategic approaches to optimizing peptide ADME properties. *The AAPS journal*. 2015 Jan;17:134-43.
- 48 Monty OBC, Simmons N, Chamakuri S, Matzuk MM, Young DW . Solution-Phase Fmoc-Based Peptide Synthesis for DNA-Encoded Chemical Libraries: Reaction Conditions, Protecting Group Strategies, and Pitfalls. *ACS Combinatorial Science* Vol 22/Issue 12. *ACS Comb. Sci.* 2020, 22, 12, 833–843.
- 49 Baska F, Bozó É, Patócs T. Vasopressin receptor antagonists: a patent summary (2018-2022). *Expert Opinion on Therapeutic Patents*. 2023 May 4;33(5):385-95.
- 50 Glavaš M, Gitlin-Domagalska A, Dębowski D, Ptaszyńska N, Łęgowska A, Rolka K. Vasopressin and its analogues: from natural hormones to multitasking peptides. *International journal of molecular sciences*. 2022 Mar 12;23(6):3068.
- 51 Neeraj K Garg NK, Singh B, Kushwah V, Tyagi RK, Sharma R, Jain S, Katare OP. The ligand (s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics. *Nanomedicine: Nanotechnology, Biology and Medicine*. 2016/5/24 (12), 2043-2060.
- 52 Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts. *Advanced drug delivery reviews*. 2016 Jun 1;101:108-21.

- 53 Amin SN, Younan SM, Youssef MF, Rashed LA, Mohamady I. A histological and functional study on hippocampal formation of normal and diabetic rats. *F1000Research*. 2013;2.
- 54 Li Y, Li N, Yu X, Huang K, Zheng T, Cheng X, Zeng S, Liu X. Hematoxylin and eosin staining of intact tissues via delipidation and ultrasound. *Scientific reports*. 2018 Aug 16;8(1):12259.
- 55 Nie T, Wang W, Liu X, Wang Y, Li K, Song X, Zhang J, Yu L, He Z. Sustained release systems for delivery of therapeutic peptide/protein. *Biomacromolecules*. 2021 May 7;22(6):2299-324.
- 56 Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, Chowdhury EH. Current strategies in extending half-lives of therapeutic proteins. *Journal of controlled release*. 2019 May 10;301:176-89.
- 57 Livak KJ, Schmittgen TD, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the $2^{-\Delta\Delta CT}$ Method. *Methods* Volume 25, Issue 4, December 2001, Pages 402-408